A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
Pfizer
Amgen
Hoffmann-La Roche
Ikena Oncology
Eli Lilly and Company
Aminex Therapeutics, Inc.
Novartis
Five Prime Therapeutics, Inc.
GE Healthcare
INSYS Therapeutics Inc